Reata Pharmaceuticals Announces Fourth Quarter and Full Year 2017 Financial and Operating Results

Reata Pharmaceuticals (Nasdaq:RETA) a clinical-stage biopharmaceutical company, announced financial results for the fourth quarter and full year ended December 31, 2017, and provided an update on the Company’s business and product development programs.

As quoted in the press release:

“In 2017, Reata made significant strides towards our goal of building a deep pipeline of late-stage therapeutics for rare and life-threatening diseases,” said Warren Huff, Chief Executive Officer.  “We entered 2017 with one pivotal trial in pulmonary arterial hypertension associated with connective tissue disease and a broad portfolio of exploratory Phase 2 studies from which we produced meaningful clinical data and launched pivotal trials in two additional rare diseases, Alport syndrome and Friedreich’s ataxia.  We begin 2018 with these three pivotal programs in the clinic and a highly focused Phase 2 program in four rare forms of CKD underway.”

Click here to read the full press release.